Warning: call_user_func_array() expects parameter 1 to be a valid callback, function 'wp_pre_kses_block_attributes' not found or invalid function name in /home/effrxch/public_html/www.effrx.com/wp-includes/class-wp-hook.php on line 288

Warning: call_user_func_array() expects parameter 1 to be a valid callback, function 'wp_pre_kses_block_attributes' not found or invalid function name in /home/effrxch/public_html/www.effrx.com/wp-includes/class-wp-hook.php on line 288

Warning: call_user_func_array() expects parameter 1 to be a valid callback, function 'wp_pre_kses_block_attributes' not found or invalid function name in /home/effrxch/public_html/www.effrx.com/wp-includes/class-wp-hook.php on line 288

Warning: call_user_func_array() expects parameter 1 to be a valid callback, function 'wp_pre_kses_block_attributes' not found or invalid function name in /home/effrxch/public_html/www.effrx.com/wp-includes/class-wp-hook.php on line 288
Lean and Agile Integrated Market-Oriented Biopharma Focused on Niche Therapeutics in Europe - EffRx

Lean and Agile Integrated Market-Oriented Biopharma Focused on Niche Therapeutics in Europe

EffRx Pharmaceuticals is a commercial-stage pharmaceutical company focused on the late-stage development and commercialization of prescription medications for niche and orphan indications. The business model is centered around providing superior clinical and commercial value propositions for physicians, payers and patients. EffRx aims to be the preferred accelerator for late clinical and regulatory development, approval, valorization of niche and orphan medicines in Switzerland and Europe.

EffRx pro-actively seeks in-licensing opportunities for Europe in niche therapeutic areas, with a primary interest for rare diseases, where EffRx has received an orphan drug designation (ODD) from FDA for a pipeline asset.

EffRx’s go-to-market competence is proven by the development, launch and lucrative expansion of Binosto® in a highly competitive European market.  Our lead commercialized product, Binosto® for the treatment of osteoporosis, is licensed in 50+ countries and marketed in the US, Europe, selected MENA and Asian countries.